Key facts
- AI Optics’s last known valuation is $30.0M (Aug 2025).
- It has raised $15.0M across 1 recorded rounds; the latest was Early Stage VC ($14.7M) in Aug 2025.
- Notable investors include Gaingels, National Institutes of Health, Keiretsu Forum, AlleyCorp, NextCorps Luminate — 11 tracked in total.
- AI Optics has filed 1 Form D with the SEC, most recently Aug 2025 ($14.7M sold to 92 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AI Optics
Funding rounds
1 roundsAbout AI Optics
Manufacturer of a medical device designed to prevent blindness and vision loss. The company's platform combines advanced imaging and artificial intelligence technologies to bring retinal disease screening to the point of care, increasing access and preventing vision loss and blindness, enabling healthcare providers to take eye scans with precision while patients are experiencing vision loss.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 6
- Website
- aioptics.ai/
- Ownership
- Privately Held (backing)
AI Optics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AI Optics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AI Optics in its N-PORT filings yet. We sweep new filings monthly.